STAT+: Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder

Amgen said Thursday that it will acquire the small drugmaker ChemoCentryx for $4 billion to obtain a newly approved medicine that treats patients with a serious autoimmune condition.

Click to view original post